Acepodia

Antibody-Cell Conjugation Therapy

ACE1831 Clin1 hematological cancers; ACE2016 Clin0 oncology; ACE1708 RD solid tumors

Acepodia is building a pipeline of cell therapies for various cancers. Given the recent advances in cell therapy and cutting edge technologies, Acepodia is developing the most potent immune cell lines possible to engage cancer cells. This involves using Acepodia’s proprietary platform technologies to equip the immune cells with optimal tumor targeting mechanisms such as their Antibody-Cell Conjugation (ACC) technology. ACC uses live-cell compatible chemistry to link any tumor-targeting antibody to the surface of human cells, enabling Acepodia to create a powerful, off-the-shelf cancer cell therapy to fight both solid tumors and hematological malignancies. Acepodia is using their discoveries to build a diverse pipeline, with their lead cell therapy in Phase 1 clinical trials.